Compare · CSTL vs ILMN
CSTL vs ILMN
Side-by-side comparison of Castle Biosciences Inc. (CSTL) and Illumina Inc. (ILMN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CSTL and ILMN operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN is the larger of the two at $33.97B, about 31.8x CSTL ($1.07B).
- CSTL has been more active in the news (12 items in the past 4 weeks vs 11 for ILMN).
- ILMN has more recent analyst coverage (25 ratings vs 6 for CSTL).
- Company
- Castle Biosciences Inc.
- Illumina Inc.
- Price
- $35.00+4.51%
- $225.01+0.76%
- Market cap
- $1.07B
- $33.97B
- 1M return
- -
- +18.79%
- 1Y return
- -
- +127.94%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 2000
- News (4w)
- 12
- 11
- Recent ratings
- 6
- 25
Castle Biosciences Inc.
Castle Biosciences, Inc., a commercial-stage dermatological cancer company, focuses to provide diagnostic and prognostic solutions for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify high-risk patients with stage I and II melanomas based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma, a proprietary GEP test for suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Latest CSTL
- Castle Biosciences to Participate in Upcoming Investor Conferences
- Chief Commercial Officer Juvenal Tobin W sold $51,191 worth of shares (1,730 units at $29.59) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 75,964 units (SEC Form 4)
- Chief Financial Officer Stokes Frank sold $741,511 worth of shares (24,908 units at $29.77), decreasing direct ownership by 41% to 35,177 units (SEC Form 4)
- Pres. & Chief Exec. Officer Maetzold Derek J exercised 1,100 shares at a strike of $2.39 and sold $217,105 worth of shares (7,232 units at $30.02) as part of a pre-agreed trading plan (SEC Form 4)
- Castle Biosciences Approved for Dual Listing on Nasdaq Texas
- SEC Form 144 filed by Castle Biosciences Inc.
- SEC Form 8-A12B filed by Castle Biosciences Inc.
- Chief Commercial Officer Juvenal Tobin W sold $49,945 worth of shares (1,301 units at $38.39) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 77,694 units (SEC Form 4)
- Pres. & Chief Exec. Officer Maetzold Derek J exercised 22,902 shares at a strike of $2.39 and sold $1,212,230 worth of shares (39,016 units at $31.07) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Operating Officer Oelschlager Kristen M sold $255,622 worth of shares (8,586 units at $29.77) as part of a pre-agreed trading plan, decreasing direct ownership by 39% to 13,288 units (SEC Form 4)
Latest ILMN
- Director Meister Keith A. sold $145,556,398 worth of shares (679,574 units at $214.19) (SEC Form 4)
- SVP, Strategy/Corp Development Wedel Christensen Jakob sold $197,840 worth of shares (1,033 units at $191.52), decreasing direct ownership by 7% to 14,023 units (SEC Form 4)
- SEC Form 8-K filed by Illumina Inc.
- Illumina Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- SEC Form 8-K filed by Illumina Inc.
- SEC Form 3 filed by new insider Coletti Julie Ann
- SEC Form FWP filed by Illumina Inc.
- Chief Commercial Officer Sullivan Michael C was granted 4,503 shares (SEC Form 4)
- Illumina Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Director Meister Keith A. sold $148,159,897 worth of shares (741,127 units at $199.91) (SEC Form 4)